Research & Development

PsychoGenics secures NIH contract to identify new pain therapeutics

Preclinical contract research organisation (CRO) PsychoGenics has received an award from the US National Institutes of Health (NIH) to conduct the testing and identification of new investigational therapeutics aimed at treating pain.

AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy

AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.

FDA grants fast track designation for Elevation Oncology’s EO-3021

The US Food and Drug Administration (FDA) has granted fast track designation for Elevation Oncology’s EO-3021, a treatment for patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer.

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.

Osivax and KM Biologics sign deal for influenza vaccine in Japan

France-based biopharmaceutical company Osivax has entered into an exclusive license option agreement with Japanese vaccine manufacturer KM Biologics for a broad-spectrum “universal” influenza vaccine candidates in Japan.

Superluminal Medicines secures $120m in Series A funding round

Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.

Novartis begins construction works at two RLT manufacturing facilities in US

Novartis has announced the commencement of construction on two new radioligand therapy (RLT) manufacturing facilities in the US, in a bid to expand its production and supply chain capabilities in the sector.

Bayer partners with NextRNA to develop lncRNA-targeting cancer therapies

Bayer has announced a strategic partnership with NextRNA Therapeutics to develop long non-coding RNAs (lncRNAs)-targeting small molecule therapeutics for cancer treatment.

Aarvik announces ADC option exercise by collaboration partner ArriVent

Aarvik Therapeutics has announced that its collaboration partner ArriVent BioPharma opted to exclusively license their joint programme.